Northwest Biotherapeutics (NWBO) Stock Statistics & Valuation Metrics

Northwest Biotherapeutics has a market cap or net worth of $343.80M. The enterprise value is $136.14M.

Northwest Biotherapeutics has 1,457,994,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

Northwest Biotherapeutics’s return on equity (ROE) is 0.89 and return on invested capital (ROIC) is 956.20%.

The current PE Ratio of Northwest Biotherapeutics is -4.00. Northwest Biotherapeutics’s PEG ratio is 0.04.

In the last 12 months, Northwest Biotherapeutics had revenue of 1.38M and earned -83.78M in profits. Earnings per share was -0.07.

In the last 12 months, operating cash flow was -54.03M and capital expenditures -775.00K, giving a free cash flow of -54.80M billion.

Northwest Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Northwest Biotherapeutics upcoming earnings date is May 16, 2018, After Close (Confirmed).

Northwest Biotherapeutics as a current ratio of 0.06, with Debt / Equity ratio of -20.49%

In the past 12 months, Northwest Biotherapeutics has paid -1.41M in taxes.

Northwest Biotherapeutics EV to EBITDA ratio is -5.44, with an EV/FCF ratio of -6.90.

Northwest Biotherapeutics has $2.78M in cash and marketable securities with $69.00M in debt, giving a net cash position of $66.23M billion.

Gross margin is 8.02%, with operating margin of -4812.45%, and net profit margin of -6062.08%.

The average price target for Northwest Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―